We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Hepatology
MedXY News
EnglishTag

Hepatology

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base
Clinical Updatescirrhosisend-stage liver disease

Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base

By MedXY|Jun 9, 2026

A major 2026 cluster randomized trial shows that palliative care delivered by trained hepatologists is noninferior to specialist palliative care for improving quality of life in end-stage liver disease, supporting scalable integrated models

Adult Liver Transplant Candidate Evaluation: What the New AASLD/AST Guideline Changes
Gastroenterology
candidate evaluation
guideline update

Adult Liver Transplant Candidate Evaluation: What the New AASLD/AST Guideline Changes

By MedXY|Jun 6, 2026

The updated AASLD/AST guideline clarifies how adults should be evaluated for liver transplantation, emphasizing equitable access, multidisciplinary assessment, psychosocial readiness, and structured risk–benefit decision-making.

Temporal Dynamics of the Circulating Cytokinome in Severe Alcohol-Associated Hepatitis: A Longitudinal Clinical Analysis
Clinical UpdatesAlcohol-Associated HepatitisAnakinra

Temporal Dynamics of the Circulating Cytokinome in Severe Alcohol-Associated Hepatitis: A Longitudinal Clinical Analysis

By MedXY|Mar 28, 2026

This review analyzes the longitudinal kinetics of 43 inflammatory biomarkers in patients with severe alcohol-associated hepatitis, comparing IL-1 receptor antagonism and corticosteroid therapy, highlighting treatment-specific signatures and

Metabolic Synergy: How Obesity and Diabetes Amplify Liver Disease Risk in Alpha-1 Antitrypsin Deficiency
GastroenterologyHepatologyliver fibrosis

Metabolic Synergy: How Obesity and Diabetes Amplify Liver Disease Risk in Alpha-1 Antitrypsin Deficiency

By MedXY|Mar 13, 2026

A large-scale longitudinal study reveals that obesity and diabetes synergistically amplify the risk of advanced liver disease in individuals with Alpha-1 Antitrypsin Deficiency (AATD), while also identifying a complex relationship between b

Navigating the New Frontier of MASLD: An Updated Clinical Pathway for Liver Health
Diabetes & Endocrinologyclinical guidelinesHepatology

Navigating the New Frontier of MASLD: An Updated Clinical Pathway for Liver Health

By MedXY|Mar 13, 2026

This article summarizes the updated clinical care pathway for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), highlighting new diagnostic nomenclature, risk stratification tools, and the integration of the first FDA-approv

Uncovering the Hepatocyte CEBPA-ORM1 Axis: A Novel Regulatory Pathway and Biomarker in Alcohol-Associated Liver Disease
Clinical Updatesalcohol-associated liver diseaseClinical Updates

Uncovering the Hepatocyte CEBPA-ORM1 Axis: A Novel Regulatory Pathway and Biomarker in Alcohol-Associated Liver Disease

By MedXY|Mar 10, 2026

This review synthesizes recent findings identifying the CEBPA-ORM1 axis as a critical suppressor of alcohol-associated liver disease, highlighting its potential as both a therapeutic target and a diagnostic biomarker for disease staging.

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort
GastroenterologyHepatologyliver fibrosis

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort

By MedXY|Feb 17, 2026

The Phenome India study identifies a 38.9% age-adjusted prevalence **Constructing the JSON Object** Now, I’m carefully constructing the JSON object, which needs to be a valid, parseable string. I’m focusing on incorporating the

Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism
Diabetes & EndocrinologyHepatologyMASH

Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism

By MedXY|Jan 14, 2026

The 24-week results of the IMPACT trial show that pemvidutide significantly improves MASH resolution without worsening fibrosis. While fibrosis improvement did not reach significance at this early time point, the drug’s safety profile

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities